Oncology Corporate Profile
This company does not have any pipeline products
10/14/2015 11:04 am
(Medscape Medical News) Oct 13, 2015 - Aprepitant (Emend, Merck & Co, Inc), a drug approved for chemotherapy-induced nausea and vomiting, has shown promise as an antitussive agent in a small trial of patients with lung cancer.
10/14/2015 11:04 am
(Washington Post/To Your Health) Oct 13, 2015 - A study published in Nature Communications raises the possibility that a promising new weapon for MRSA may have been right under our noses: tamoxifen.
10/14/2015 11:04 am
(Centre for Drug Research and Development [Vancouver, BC]) Oct 13, 2015 - A new type of cancer therapy based on seemingly unrelated elements of malaria and cancer is showing promise for development.
10/14/2015 11:04 am
(UCCC/Colorado Cancer Blogs) Oct 13, 2015 - A University of Colorado Cancer Center study recently published online ahead of print in the journal Oncotarget reports “robust antitumor activity” of the drug TAK-733 in cells and mouse models of colorectal cancer.
2/26/2015 12:01 pm
(NASDAQ) Feb 26, 2015 - Incyte Corporation today announced that it is sponsoring the first major observational study of patients living with polycythemia vera (PV) in the U.S.
6/2/2014 02:00 pm
(TheStreet) June 2, 2014 - Foundation Medicine released the results of its decision analytics study earlier Saturday morning at the American Society of Clinical Oncology annual meeting, demonstrating 27.3% of doctors altered their prescriptions based on a FoundationOne diagnostic test.
5/31/2014 12:04 pm
(New York Times/Associated Press) May 30, 2014 – The Food and Drug Administration on Friday approved the first generic versions of Pfizer’s anti-inflammatory painkiller Celebrex.
5/31/2014 12:01 pm
(Dana-Farber) May 31, 2014 - Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today.
5/29/2014 07:00 am
(MarketWatch) May 29, 2014 - Advaxis, Inc., a biotechnology company developing cancer immunotherapies, and inVentiv Health Clinical, a leading global clinical research organization (CRO), announced today that they have entered into a master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline.
5/29/2014 06:04 am
(Yahoo! Finance) May 29, 2014 - Oncothyreon Inc. and Celldex Therapeutics, Inc. today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1.
4/22/2014 12:00 pm
(Business Weekly [UK]) Apr 22, 2014 - Medical technology from Cambridge UK cancer business Sentinel Oncology is being developed and commercialised by US company Oncothyreon in a collaboration that could bring the Science Park firm mega-millions.
2/20/2014 11:05 am
(Denver Post) Feb 20, 2014 - Oncothyreon Inc. and Array BioPharma Inc. today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer.
2/3/2014 11:05 am
(Yahoo! Finance) Feb 3, 2014 - Oncothyreon Inc. and Array BioPharma Inc. today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer.
10/18/2013 11:03 am
(MSKCC) Oct 17, 2013 - Memorial Sloan-Kettering Cancer Center has announced the appointment of surgical oncologist Richard Barakat to the new position of Deputy Physician-in-Chief for the Memorial Sloan-Kettering Regional Care Network and Alliance.
10/7/2013 11:05 am
(Morningstar/Benzinga) Oct 7, 2013 - Oncothyreon Inc. today announced the presentation of final results from the first Phase 1 trial of ONT-380 at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research in San Diego.
9/4/2013 11:02 am
(KOLD-TV, Ch. 13/Tucson News Now [Tucson, AZ]) Sep 3, 2013 - Oncothyreon Inc. today announced the initiation of an investigator-sponsored trial of ONT-380 in combination with trastuzumab (Herceptin®) in patients with brain metastases from HER2+ breast cancer.
6/12/2013 11:03 am
(St. Jude) June 10, 2013 - Changes in an epigenetic mechanism that turns expression of genes on and off may be as important as genetic alterations in causing pediatric acute lymphoblastic leukemia (ALL), according to a study led by scientists at St. Jude Childrenâ€™s Research Hospital and published in the June 10 online edition of the Journal of Clinical Investigation.
6/7/2013 10:00 am
(Time Healthland) June 7, 2013 - If new moms adhered to the recommended guidelines that urge them to breast-feed each child they give birth to for at least one year, they could theoretically stave off up to 5,000 cases of breast cancer annually.
5/30/2013 11:03 am
(Puget Sound Business Journal) May 30, 2013 - Oncothyreon Inc. said it's signed a deal with Array BioPharma Inc. of Boulder, Colo. to commercialize Array's breast-cancer drug.
5/16/2013 12:03 pm
(The Street) May 15, 2013 - New details about failed lung cancer immunotherapy from Oncothyreon were revealed for the first time Wednesday night in a research abstract for the American Society of Clinical Oncology (ASCO) annual meeting.
5/13/2013 11:05 am
(BioCentury) May 10, 2013 - Oncothyreon Inc. disclosed in its 1Q13 earnings late Thursday that once-daily oral PX-866 plus docetaxel missed the primary endpoint of improving progression-free survival (PFS) vs. docetaxel alone in a cohort of patients with non-small cell lung cancer (NSCLC) in the open-label Phase II portion of a Phase I/II trial to treat advanced metastatic solid tumors.
3/22/2013 11:01 am
(ASCO in Action) Mar 21, 2013 - ASCO members should have received an invitation on March 16 to participate in an oncology drug shortages survey to help ASCO and its membership understand the impact of drug shortages.
2/7/2013 12:03 pm
(Forbes) Feb 6, 2013 - On Thursday (February 7), Amgen management will discuss the company’s future growth strategies at an eagerly awaited business review day. One particular area of interest – for investors and analysts alike – will be discussion on how Amgen is looking to develop its role in the biosimilars market.
12/19/2012 07:04 am
(TheStreet) Dec 19, 2012 - Stimuvax, an experimental cancer immunotherapy from Merck KGaA and Oncothyreon, failed to improve survival in a late-stage study of non-small cell lung cancer patients, the companies announced Wednesday.
11/19/2012 12:02 pm
(TheStreet) Nov 19, 2012 - The first quarter of 2013 is shaping up to be action-packed for biotech investors.